Startups
UNLOCKING THE DEEP HUMAN GENOME
We’re saving lives through early detection, better prevention and more effective cures for all disease, starting with cancer.
THE DEEP HUMAN GENOME
When a disease is developing in the body, the affected cells die and shed into the bloodstream. Life-threatening diseases like cancer leave a unique combination of mutations in the DNA of these dead cells. By investigating every single copy of cell-free DNA in a blood sample, we can gain a uniquely deep and comprehensive insight into the body’s current health status.
We call this comprehensive data set the DEEP HUMAN GENOME.
To-date, no available technology has been able to fully utilize the life-saving information contained within in the Deep Human Genome.
A NEW ERA OF PRECISION MEDICINE
Medical technology now allows for cancer to be detected in a patient’s blood through cell-free DNA (cfDNA). Quantgene has developed a method for Deep Human Genome sequencing which allows us to see mutational patterns of disease down to a single molecule. This means diseases like cancer can be detected far earlier than ever before.
The GRIFFIN Deep Genomics Platform enables us to profile cfDNA in a patient’s blood with near-absolute precision. This helps inform early cancer detection, prediction of disease onset as well as non-invasive treatment monitoring for longer healthier lives.
We’re saving lives through early detection, better prevention and more effective cures for all disease, starting with cancer.
THE DEEP HUMAN GENOME
When a disease is developing in the body, the affected cells die and shed into the bloodstream. Life-threatening diseases like cancer leave a unique combination of mutations in the DNA of these dead cells. By investigating every single copy of cell-free DNA in a blood sample, we can gain a uniquely deep and comprehensive insight into the body’s current health status.
We call this comprehensive data set the DEEP HUMAN GENOME.
To-date, no available technology has been able to fully utilize the life-saving information contained within in the Deep Human Genome.
A NEW ERA OF PRECISION MEDICINE
Medical technology now allows for cancer to be detected in a patient’s blood through cell-free DNA (cfDNA). Quantgene has developed a method for Deep Human Genome sequencing which allows us to see mutational patterns of disease down to a single molecule. This means diseases like cancer can be detected far earlier than ever before.
The GRIFFIN Deep Genomics Platform enables us to profile cfDNA in a patient’s blood with near-absolute precision. This helps inform early cancer detection, prediction of disease onset as well as non-invasive treatment monitoring for longer healthier lives.
Overview
Location
United States, California, Santa Monica
Employees
11-50
Phone
+1 424-272-1566
Total raised
$2.2M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 24, 2021 | Quantgene Expands Their Leadership By Hiring David Herrmann as Chief Commercial Officer | |
| Mar 24, 2021 | Quantgene and CureMatch Announce Strategic Partnership To Help Cancer Patients Find the Best Precision Treatment | |
| Feb 19, 2021 | Quantgene Now Has an At-Home Saliva Test to Help Detect Cancer Risk | Biotech startup Quantgene released an at-home saliva to test for cancer risk, hoping to compete with other genetics companies as it develops even more precise ways to detect the disease. The Santa Monica-based company, which aims to extend ... |
| Feb 18, 2021 | Quantgene Raises $6 Million, Sets Marketing Partnership | |
| Jul 22, 2020 | Here's How Biotech Company Quantgene Plans to Extend Human Life by 10 Years Within a Decade | Jo Bhakdi thinks he can extend life with data. Over the past years, the trained economist and co-founder of Quantgene has helped create a blood test that screens for early signs of some of the deadliest cancers, using millions of culled dat... |
Reviews 0
FAQ about Quantgene
How much funding has Quantgene raised?
Quantgene has raised $2.2M in total across 1 funding round.
What has the press written about Quantgene?
Parsers VC has collected 6 articles mentioning Quantgene, among them “Quantgene Expands Their Leadership By Hiring David Herrmann as Chief Commercial Officer” (Jun 24, 2021) and “Quantgene and CureMatch Announce Strategic Partnership To Help Cancer Patients Find the Best Precision Treatment” (Mar 24, 2021).
Is Quantgene still active?
Yes, Quantgene is active; its latest activity on Parsers VC dates from Feb 15, 2023.